10-Q: Yubo Biotech Reports Zero Revenue, Deepening Losses

Yubo International Biotech Limited reported no sales for the first half of 2025, alongside continued significant net losses and a going concern warning.

Summary

• Reported zero revenue from sales of products and services for the three and six months ended June 30, 2025, a significant decline from $3,488 in sales for the six months ended June 30, 2024.
• Net loss for the six months ended June 30, 2025, was $592,136, an improvement from $1,007,853 for the same period in 2024, primarily due to decreased operating expenses.
• Operating expenses decreased to $592,094 for the six months ended June 30, 2025, from $882,518 for the six months ended June 30, 2024.
• Cash and equivalents increased slightly to $10,416 as of June 30, 2025, from $7,015 at December 31, 2024.
• Maintained a negative working capital of $4,366,368 as of June 30, 2025.
• Accumulated deficit grew to $7,326,775 as of June 30, 2025, from $6,660,811 at December 31, 2024.
• A Securities Purchase Agreement was entered into on July 23, 2025, to issue 50,600,000 shares of Class A Common Stock to related parties (FlyDragon International Limited and ChinaOne Technology Limited) at $0.05 per share, in exchange for the cancellation of $2,758,796 in shareholder loans from Mr. Jun Wang and $442,214 from Mr. Yang Wang.

Sentiment

Score: 1

Explanation: The company exhibits severe financial distress with zero revenue, significant recurring losses, negative working capital, and a going concern warning. While operating expenses decreased, the lack of sales indicates a fundamental business challenge. The 'capital raise' is a debt-to-equity conversion with related parties, not new cash, further highlighting the inability to attract external investment. The substantial risks associated with the VIE structure and PRC regulatory environment add to the highly negative outlook.

Positives

• Net loss decreased to $592,136 for the six months ended June 30, 2025, from $1,007,853 in the prior year period, driven by reduced operating expenses.
• Operating expenses significantly decreased to $592,094 for the six months ended June 30, 2025, from $882,518 for the same period in 2024.
• Cash balance increased to $10,416 as of June 30, 2025, from $7,015 at December 31, 2024.
• Received a financial support letter from a major shareholder, Jun Wang, committing to provide continuous financial support for 12 months from March 31, 2025.
• The conversion of $3,201,010 in shareholder loans to equity reduces the company's liabilities to related parties.

Negatives

• Reported zero revenue for the three and six months ended June 30, 2025, indicating a complete halt in sales activities.
• Continued to incur significant net losses, with an accumulated deficit reaching $7,326,775.
• Maintained a substantial negative working capital of $4,366,368, highlighting severe liquidity issues.
• The company's financial statements include an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.
• A past due rent amount of RMB 1,561,473 ($218,958) as of June 30, 2025, indicates financial distress.
• Advances from prospective customers/distributors totaling $432,028 are subject to return upon request, posing a potential liquidity risk.
• The decrease in sales was primarily attributed to a downturn in market and economic conditions in China.

Risks

• The Variable Interest Entity (VIE) structure in China may not comply with PRC laws and regulations, potentially leading to severe penalties, forced relinquishment of interests, or inability to consolidate financial results.
• Contractual arrangements with the VIE (Yubo Beijing) have not been tested in a court of law, introducing legal uncertainty.
• Uncertainties regarding the interpretation and application of evolving PRC laws and regulations, including those governing foreign investment, cybersecurity, and data privacy, could materially adversely affect operations.
• The company faces risks under the Holding Foreign Companies Accountable Act (HFCA Act), which could lead to delisting if its auditor is not subject to PCAOB inspection for two consecutive years.
• The Cybersecurity Review Measures (CRM) and Personal Information Protection Law (PIPL) in China could subject the company to cybersecurity reviews, data localization requirements, cross-border data transfer restrictions, increased operating costs, and penalties.
• The company has not yet established an ongoing source of revenues and cash flows sufficient to cover operating costs, raising substantial doubt about its ability to continue as a going concern.
• All executive officers and directors are residents of China, and most of their assets are in China, making enforceability of U.S. civil liabilities difficult.
• Product candidates are in early stages of development, requiring substantial additional funds and regulatory approvals.
• Dependence on third-party manufacturers, suppliers, research organizations, and testing laboratories introduces operational risks.
• Competition in the biotech industry and the ability to develop successful sales and marketing capabilities are significant challenges.

Future Outlook

Management believes that with the financial support letter from its major shareholder, cash on hand and working capital will be sufficient to meet anticipated cash requirements through 2025. The company intends to continue working toward identifying and obtaining new sources of financing, including third-party equity and/or debt financing, but provides no assurances of success.

Management Comments

• "Managements plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its operating expenses and seeking third party equity and/or debt financing."
• "With such financial support letter, we believe that our cash on hand and working capital will be sufficient to meet our and Yubo Beijings anticipated cash requirements through 2025."

Industry Context

The company operates in the biotech industry, specifically focusing on stem cell research and application, with a stated goal of building the world's first public endometrial stem cell repository. Its day-to-day operations are primarily conducted in China through a Variable Interest Entity (VIE) structure, which exposes it to the complex and evolving regulatory landscape of the PRC, including heightened scrutiny on foreign listings, cybersecurity, and data privacy. The reported downturn in market and economic conditions in China has negatively impacted the company's sales, reflecting broader challenges faced by businesses operating in the region.

Comparison to Industry Standards

• The company's zero revenue for the reported period is significantly below industry standards for publicly traded biotech companies, which typically generate revenue from product sales, licensing, or research collaborations.
• The substantial accumulated deficit and negative working capital indicate a financial position far weaker than established biotech firms or even many early-stage companies that have secured significant funding rounds.
• The reliance on related-party loans and a debt-to-equity conversion with insiders, rather than external capital raises, suggests an inability to attract arms-length investment, which is a common benchmark for viability in the biotech sector.
• The company's unique focus on 'the first public endometrial stem cell repository' makes direct comparison to specific, established projects difficult, as it appears to be pioneering an unproven market segment without clear revenue generation.

Related Party Transactions

• As of June 30, 2025, the company had $282,617 due from Beijing Zhenhuikang Biotechnology Co., LTD (Zhenhuikang), an entity controlled by Mr. Yulin Cao, a director and significant stockholder of Yubo Beijing. This receivable is non-interest bearing and due on demand.
• As of June 30, 2025, the company had payables due to Mr. Jun Wang ($2,758,796), Mr. Yang Wang ($442,214), Ms. Huang Li ($54,438), and Mr. Jin Wei ($30,000). These payables are non-interest bearing and due on demand.
• On July 23, 2025, the company entered into a Securities Purchase Agreement with FlyDragon International Limited (controlled by Mr. Jun Wang) and ChinaOne Technology Limited (controlled by Mr. Yang Wang) to issue 50,600,000 shares of Class A Common Stock in exchange for the cancellation of shareholder loans totaling $3,201,010.

Stakeholder Impact

• Shareholders face significant risk of value impairment or worthlessness due to recurring losses, negative working capital, and the going concern warning.
• Creditors, particularly related parties, are exposed to repayment risk given the company's financial instability, though some debt has been converted to equity.
• Employees may face uncertainty regarding job security and future operations given the company's financial challenges and lack of revenue.
• Prospective customers/distributors who have made advances may request returns, impacting the company's limited cash reserves.

Next Steps

• Obtain additional capital resources from management, significant shareholders, or third-party equity/debt financing to address going concern issues.
• Continue research and development activities related to stem cell technologies.
• Seek to obtain and maintain regulatory approval for product candidates.
• Develop successful sales and marketing capabilities to generate revenue.
• Monitor and comply with evolving PRC laws and regulations, particularly regarding the VIE structure, cybersecurity, and data privacy.

Key Dates

Recommendation

The company exhibits critical financial instability, marked by zero revenue, substantial and recurring net losses, and a significant negative working capital position. The explicit 'going concern' warning indicates a high probability of business failure without substantial, unassured future financing. While operating expenses were reduced, the complete absence of sales signals a fundamental breakdown in business operations. The recent 'capital raise' is merely a debt-to-equity conversion with related parties, not an infusion of new cash, which suggests an inability to attract external, arms-length investment. Furthermore, the inherent risks of the VIE structure in China and the evolving regulatory environment add layers of unquantifiable risk. Given these severe challenges and the lack of a viable revenue stream, the stock carries extreme downside risk.

Keywords

Biotechnology, Stem Cell, China Operations, SEC Filing, 10-Q, Financial Report, VIE Structure, Healthcare Products, Endometrial Stem Cells, PRC Regulations, Going Concern, Financial Performance, Quarterly Report